Publication

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Niemantsverdriet, M., Schuuring, E., Elst, A. T., van der Wekken, A. J., van Kempen, L. C., van den Berg, A. & Groen, H. J. M., Dec-2018, In : Journal of Thoracic Oncology. 13, 12, p. E249-E251 3 p.

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Copy link to clipboard

Documents

  • KRAS Mutation as a Resistance Mechanism to BRAFMEK Inhibition in NSCLC

    Final publisher's version, 795 KB, PDF document

DOI

Original languageEnglish
Pages (from-to)E249-E251
Number of pages3
JournalJournal of Thoracic Oncology
Volume13
Issue number12
Publication statusPublished - Dec-2018

    Keywords

  • LUNG-CANCER, DABRAFENIB

View graph of relations

ID: 71379876